secwatch.observer — SEC 8-K summary
======================================

Issuer:     PDS Biotechnology Corp (PDSB)
CIK:        0001472091
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001140361-23-024496
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PDS Biotech reports Q1 net loss of $9.7M; plans Phase 3 trial for PDS0101 in Q4 2023
--------------------------------------------------------------------------------

- Q1 net loss $9.7M ($0.32/sh) vs $8.5M ($0.32/sh) in Q1 2022; R&D spend rose to $5.8M.
- Cash $65.2M at March 31, 2023; expected to fund operations into Q3 2024.
- VERSATILE-002 Phase 2 data to be presented at ASCO 2023; Phase 3 VERSATILE-003 initiation planned for Q4 2023.
- Received $1.4M from sale of NJ tax benefits; NCI-led triple combination trial progressing.
- Preclinical Infectimune data showing flu protection published in peer-reviewed journal.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472091/000114036123024496/0001140361-23-024496-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472091/000114036123024496/brhc20052894_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-024496

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer